A 2-part, noninterventional, multicenter, multinational, open- label, prospective phase 4 study of eRbitux in combination with chemotherapy in patients with first-line management of metastatic colorectal cancer

Trial Profile

A 2-part, noninterventional, multicenter, multinational, open- label, prospective phase 4 study of eRbitux in combination with chemotherapy in patients with first-line management of metastatic colorectal cancer

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 13 Oct 2017

At a glance

  • Drugs Cetuximab (Primary)
  • Indications Colorectal cancer
  • Focus Biomarker; Pharmacodynamics; Therapeutic Use
  • Acronyms SECURE
  • Most Recent Events

    • 13 Oct 2017 New trial record
    • 12 Sep 2017 Results presented at the 42nd European Society for Medical Oncology Congress
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top